Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Lymphoma, Non-Hodgkin 6 Lymphoma 6 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Burkitt Lymphoma 3 Lymphoma, Mantle-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, B-Cell, Marginal Zone 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Leukemia 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Paraproteinemias 1 Neoplasms 1 Lymphoproliferative Disorders 1 Hemostatic Disorders 1 Hematologic Diseases 1

Interventions

Cyclophosphamide 100 Rituximab 82 fludarabine phosphate 46 Peripheral Blood Stem Cell Transplantation 45 fludarabine 43 Lenalidomide 35 Filgrastim 33 Methotrexate 32 Cytarabine 32 Busulfan 32 venetoclax 31 Etoposide 31 Cyclosporine 30 Dexamethasone 29 Radiotherapy 28 Mycophenolic Acid 28 Melphalan 28 Bendamustine Hydrochloride 25 Antilymphocyte Serum 25 Vincristine 24 Gemcitabine 24 ibrutinib 22 Whole-Body Irradiation 22 Doxorubicin 20 Tacrolimus 19 Methylprednisolone 18 Bortezomib 18 Brentuximab Vedotin 16 pembrolizumab 15 Prednisone 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × epratuzumab × Lymphoid × Clear all

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡